Bankruptcy court admits BSE-listed Supha Pharmachem under Insolvency Resolution ProcessThe Mumbai bench of the National Company Law Tribunal has admitted Supha Pharmachem into the Corporate Insolvency Resolution Process (CIRP)...
28 Mar, 2026, 09.26 AM IST
Intas Pharma completes acquisition of UDENYCA biosimilar for $558 millionIntas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. ...
13 Aug, 2025, 10.38 AM IST
Biosimilar brand buy to help Intas Pharma take on biggiesIn one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication peg...
06 Jan, 2025, 11.51 PM IST
Indian pharma majors weigh bids for Sanofi’s $2 billion European generics businessThe portfolio of acute, chronic and oncology products could fetch a valuation of $1.5-2 bn, making it among the largest outbound transactio...
11 Jan, 2018, 06.44 AM IST
ChrysCapital sells 3% in Intas to Capital InternationalChrysCapital will continue to hold a 3% stake in Intas, making it the longest and probably the most successful private equity investment in...
03 Apr, 2017, 12.33 PM IST
Intas buys Teva's UK & Ireland assets for $764 million to break into global top 20 generic players clubWith the acquisition of Teva’s products, sold through erstwhile Actavis’ operations, Intas is set to emerge as a top player in the UK gener...
06 Oct, 2016, 05.52 PM IST
Intas Pharmaceuticals to launch its first biosimilar in US in 9-12 monthsIntas is the only domestic firm with two biosimilars filed for registration in the US and it looks to deliver affordable and innovative pha...
21 Jun, 2015, 01.54 PM IST
15 doctors suspended for accepting junketsThe doctors’ regulatory body is also in the process of sending a letter to the Drug Controller General of India, urging it to warn and take...
24 Feb, 2015, 04.58 AM IST
Temasek completes 10.16% stake purchase in Intas PharmaTemasek acquired the stake by way of secondary purchase of shares from private equity investor ChrysCapital. This investment will deepen Te...
10 Nov, 2014, 05.29 PM IST
Delhi High Court comes to Intas rescue, stops Arinna Lifescience for trademark violationDelhi High Court gave relief to Ahmedabad-based drug maker, Intas Pharmaceuticals, by granting an ex-parte injunction against the sale of V...
30 Oct, 2014, 12.50 AM IST
ChrysCapital to sell 10% in drug maker Intas Pharmaceuticals to Temasek for over $160 millionTemasek has bought 12.5% stake in Intas Pharmaceuticals, one of India's top 10 drug makers by sale, for a little over Rs 1,100 crore, peopl...
03 Jun, 2014, 01.54 PM IST
Temasek, two other PEs eye ChrysCapital’s 10 pc stake in Intas PharmaThree private equity funds are in independent talks to purchase rival ChrysCap’s stake Intas Pharmaceuticals for about $150 million or Rs 9...
29 Jan, 2014, 04.00 AM IST
- Intas ex-employee objects to amalgamation plan
An affidavit of objection challenging Intas' amalgamation was filed by Mani Iyer, a former executive director of Intas Biopharmaceuticals, ...
11 Feb, 2013, 11.25 PM IST
- Intas gets SEBI nod for IPO for raising Rs 800 crore
Intas Pharmaceuticals has received SEBI clearance for its IPO. The issue was expected to hit the market in May, but Intas is still undecide...
04 Aug, 2011, 08.41 PM IST
- Intas Biopharma in talks with Japanese co for outlicensing
Intas Biopharmaceutical Ltd, a group company of the Rs 1,600-crore Intas Pharmaceuticals Ltd, would soon enter into an out-licensing and su...
27 Sep, 2010, 12.24 PM IST
- Intas Pharma IPO to raise Rs 800 cr, fund acquisitions
Intas Pharma plans to raise Rs 750-800 cr through IPO that will help it raise fresh funds for acquisitions besides allowing PE investor Chr...
06 Sep, 2010, 03.47 AM IST
- Mauritius-based FIIs to pick up 47% in Intas' biotech arm
A clutch of investors are set to pick up 47% stake in the Intas Biopharmaceuticals, the biotech arm of Ahmedabad-based pharma major Intas P...
10 Oct, 2007, 02.27 AM IST